
3 Generic Medicines Maker, Document Workflow Software Provider and Grinding Wheels and Abrasives Maker Stocks With a Strong Future Roadmap: Strides Pharma Science, Newgen Software Technologies and Grindwell Norton
Strides Pharma Science, Newgen Software Technologies and Grindwell Norton: ROE of 16.4% to 18.7% and FY22 to FY26 revenue CAGR of 11.3% to 19.4%. Prices as of 16 Nov 2026.
Updated: 17 Nov 2026 • 3:02 pm
Posted by:

Quick Answer
The three pharma, workflow software and abrasives stocks to watch are Strides Pharma Science, Newgen Software Technologies and Grindwell Norton. Their return on equity ranges from 16.4% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.3% to 19.4%. Newgen Software Technologies leads on both return on equity at 18.7% and revenue growth at 19.4% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.
Pharma, workflow software and abrasives stocks bring together companies with a visible plan for the years ahead. Strides Pharma Science, Newgen Software Technologies and Grindwell Norton cover a pharmaceuticals company, a workflow software company and an abrasives maker.
This list covers three pharma, workflow software and abrasives stocks with complete current figures: Strides Pharma Science, Newgen Software Technologies and Grindwell Norton. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma, Workflow Software and Abrasives Stocks?
Pharma, workflow software and abrasives stocks are listed companies that make generic medicines for India and regulated markets, build software that helps banks and governments manage documents and workflows, and make grinding wheels, coated abrasives and ceramics for industry. Their earnings depend on medicine orders, software licences and factory activity.
Pharma, Workflow Software and Abrasives Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Strides Pharma Science | 986.1 | 9,491 | 15.0 | 36.0 | 17.9 | 0.57 |
| Newgen Software Technologies | 433.3 | 6,835 | 21.8 | 17.5 | 18.7 | 0.02 |
| Grindwell Norton | 1,844.7 | 20,188 | 46.1 | 44.4 | 16.4 | 0.02 |
On valuation, Strides Pharma Science trades at a P/E below the industry P/E, while Newgen Software Technologies and Grindwell Norton trade above it, which reflects the growth the market already expects. Readers comparing pharma, workflow software and abrasives stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in pharma, workflow software and abrasives stocks can use the coming numbers to test whether growth is holding.
Why Do Pharma, Workflow Software and Abrasives Stocks Have a Strong Roadmap in India?
Pharma, workflow software and abrasives stocks have a strong roadmap in India because steady demand for medicines, rising use of workflow software and wider factory output keep widening the market for these companies.
- Pharmaceuticals. Patients need reliable generic medicines.
- Workflow software. Offices move to digital processes.
- Abrasives. Factories use wheels for finishing parts.
Why Strides Pharma Science Features Among These Pharma, Workflow Software and Abrasives Stocks
Among the pharma, workflow software and abrasives stocks on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.
The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.
Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore.
Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What to watch: Track new US launches and the pace of price erosion in generic categories.
Why Newgen Software Technologies Features Among These Pharma, Workflow Software and Abrasives Stocks
Among the generic injectables, content software and grinding wheel shares on this list, Newgen Software Technologies, based in Delhi, offers low-code platforms for content management, process automation and customer engagement to banks, insurers and governments.
Revenue rose from Rs 809 crore in FY22 to Rs 1,641 crore in FY26, a compound annual growth rate of 19.4%. Net profit grew from Rs 164 crore in FY22 to Rs 301 crore in FY26, which works out to a compound annual growth rate of 16.3%.
In the June 2026 quarter, revenue grew 12.3% year on year to Rs 393 crore, while net profit rose 26.3% to Rs 62.8 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 6,835 crore. The stock trades at a P/E of 21.8, above the industry P/E of 17.5.
Roadmap: Digital transformation at banks and public sector organisations, plus new artificial intelligence features on its platform, widen its addressable market. A growing share of recurring licence and cloud revenue improves predictability.
What to watch: Monitor deal wins in the banking sector and the growth of recurring revenue.
Why Grindwell Norton Features Among These Pharma, Workflow Software and Abrasives Stocks
Among the three companies on this list, Grindwell Norton, a Saint-Gobain group company, makes abrasives, ceramics and plastics products, including grinding wheels, coated abrasives and silicon carbide.
In the June 2026 quarter, revenue grew 13.8% year on year to Rs 828 crore, while net profit rose 22.1% to Rs 115 crore. Revenue rose from Rs 2,066 crore in FY22 to Rs 3,168 crore in FY26, a compound annual growth rate of 11.3%.
Net profit grew from Rs 295 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 9.0%. The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 20,188 crore. The stock trades at a P/E of 46.1, above the industry P/E of 44.4.
Roadmap: Demand from automobiles, steel, infrastructure and general manufacturing supports its core abrasives range, while ceramics and plastics offer higher-value niches. The group's technology support and a debt-free balance sheet allow it to add capacity at its own pace.
What to watch: Keep tabs on industrial activity and input costs for raw materials such as silicon carbide.
Strides Pharma Science vs Newgen Software Technologies vs Grindwell Norton on Key Financials
The table below sets the three pharma, workflow software and abrasives stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Strides Pharma Science | 3,202 | 5,009 | 11.8% | 575 | 11.5% |
| Newgen Software Technologies | 809 | 1,641 | 19.4% | 301 | 18.3% |
| Grindwell Norton | 2,066 | 3,168 | 11.3% | 417 | 13.2% |
Newgen Software Technologies posts the highest return on equity in this group at 18.7%. Strides Pharma Science has the largest FY26 revenue at Rs 5,009 crore, and Newgen Software Technologies shows the fastest revenue growth with a 19.4% compound annual rate. A useful habit with pharma, workflow software and abrasives stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Strides Pharma Science | 1,128 | 1,270 | 12.6% |
| Newgen Software Technologies | 350 | 393 | 12.3% |
| Grindwell Norton | 727 | 828 | 13.8% |
Key Risks to Check Before Investing in Pharma, Workflow Software and Abrasives Stocks
Every theme carries risks that deserve a check before any decision. For these pharma, workflow software and abrasives stocks, the main points are: Long-term generic injectables, content software and grinding wheel shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Client spending. Technology budgets can vary with global conditions.
- Demand cycles. Sales can vary with seasons and rates.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma, workflow software and abrasives stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma, Workflow Software and Abrasives Stocks
Pharma, workflow software and abrasives stocks suit investors who prefer to study business strength before price moves. Strides Pharma Science, Newgen Software Technologies and Grindwell Norton each have a clear plan to grow. Based on the 16 November 2026 close, Strides Pharma Science trades at Rs 986.1, Newgen Software Technologies at Rs 433.3 and Grindwell Norton at Rs 1,844.7. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these pharma, workflow software and abrasives stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pharma, workflow software and abrasives stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma, workflow software and abrasives stocks?
Ans. Pharma, workflow software and abrasives stocks are listed companies that make generic medicines for India and regulated markets, build software that helps banks and governments manage documents and workflows, and make grinding wheels, coated abrasives and ceramics for industry. Their earnings depend on medicine orders, software licences and factory activity. This list looks at three of them, Strides Pharma Science, Newgen Software Technologies and Grindwell Norton, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.
Which pharma, workflow software and abrasives stocks are covered in this list?
Ans. This list covers Strides Pharma Science, Newgen Software Technologies and Grindwell Norton. Based on the 16 November 2026 close, Strides Pharma Science traded at Rs 986.1, Newgen Software Technologies at Rs 433.3 and Grindwell Norton at Rs 1,844.7. Their return on equity ranges from 16.4% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.3% to 19.4%.
Why do pharma, workflow software and abrasives stocks have a strong future roadmap in India?
Ans. Pharma, workflow software and abrasives stocks have a strong roadmap in India because steady demand for medicines, rising use of workflow software and wider factory output keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Patients need reliable generic medicines. Workflow software. Offices move to digital processes. Abrasives. Factories use wheels for finishing parts. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Strides Pharma Science performed financially?
Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
How has Newgen Software Technologies performed financially?
Ans. Revenue rose from Rs 809 crore in FY22 to Rs 1,641 crore in FY26, a compound annual growth rate of 19.4%. Net profit grew from Rs 164 crore in FY22 to Rs 301 crore in FY26, which works out to a compound annual growth rate of 16.3%. In the June 2026 quarter, revenue grew 12.3% year on year to Rs 393 crore, while net profit rose 26.3% to Rs 62.8 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 6,835 crore. The stock trades at a P/E of 21.8, above the industry P/E of 17.5. Looking ahead, digital transformation at banks and public sector organisations, plus new artificial intelligence features on its platform, widen its addressable market. A growing share of recurring licence and cloud revenue improves predictability.
How has Grindwell Norton performed financially?
Ans. Revenue rose from Rs 2,066 crore in FY22 to Rs 3,168 crore in FY26, a compound annual growth rate of 11.3%. Net profit grew from Rs 295 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 9.0%. In the June 2026 quarter, revenue grew 13.8% year on year to Rs 828 crore, while net profit rose 22.1% to Rs 115 crore. The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 20,188 crore. The stock trades at a P/E of 46.1, above the industry P/E of 44.4. Looking ahead, demand from automobiles, steel, infrastructure and general manufacturing supports its core abrasives range, while ceramics and plastics offer higher-value niches. The group's technology support and a debt-free balance sheet allow it to add capacity at its own pace.
What risks should investors check before buying pharma, workflow software and abrasives stocks?
Ans. Investors should check a few risks before buying pharma, workflow software and abrasives stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Client spending. Technology budgets can vary with global conditions. Demand cycles. Sales can vary with seasons and rates. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma, workflow software and abrasives stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
Recent Articles

High Dividend Yield Stocks in India: Vedanta, Hindustan Zinc, Coal India and CESC Checked on 17 November 2026
17 November 2026

Top Mid-Cap Metal Stocks Compared: Jindal Stainless vs Gravita vs HEG vs Graphite India vs MOIL on Price, Valuation, Q2 FY27 Results and Risks
17 November 2026

Top Mid-Cap Hospital Stocks Compared: Rainbow Children vs HCG vs Jupiter Life Line vs KIMS vs Narayana Hrudayalaya on Price, Valuation, Q2 FY27 Results and Risks
17 November 2026

Top Mid-Cap Capital Goods Stocks Compared: Elgi Equipments vs GMM Pfaudler vs Grindwell Norton vs AIA Engineering vs Cummins India on Price, Valuation, Q2 FY27 Results and Risks
17 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
High Dividend Yield Stocks in India: Vedanta, Hindustan Zinc, Coal India and CESC Checked on 17 November 2026
Top Mid-Cap Metal Stocks Compared: Jindal Stainless vs Gravita vs HEG vs Graphite India vs MOIL on Price, Valuation, Q2 FY27 Results and Risks
Top Mid-Cap Hospital Stocks Compared: Rainbow Children vs HCG vs Jupiter Life Line vs KIMS vs Narayana Hrudayalaya on Price, Valuation, Q2 FY27 Results and Risks
Top Mid-Cap Capital Goods Stocks Compared: Elgi Equipments vs GMM Pfaudler vs Grindwell Norton vs AIA Engineering vs Cummins India on Price, Valuation, Q2 FY27 Results and Risks
Top Mid-Cap Auto Stocks Compared: Hyundai Motor India vs Force Motors vs JBM Auto vs Escorts Kubota vs Olectra on Price, Valuation, Q2 FY27 Results and Risks
Popular this week
Top Two-Wheeler Stocks Compared: Hero MotoCorp vs Bajaj Auto vs Eicher Motors vs TVS Motor vs Atul Auto on Price, Valuation, Q2 FY27 Results and Risks

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





